Peripheral GABAA Receptor Targeting

  • Exploits/repurposes 50 years of CNS
    drug knowledge
  • Peripheral acting drugs designed to avoid CNS exposure/central effects
  • Smooth muscle relaxation
  • Anti-inflammatory
  • Not systemically immune-suppressive

Lead Oral NCE Candidate Identified (PI-301)

  • 10 years academic development,
    >$4 MM grant funding, 13 peer reviewed publications
  • Efficacy shown in multiple animal
    disease models
  • Established drug backbone; good
    safety profile
  • IND enabling studies ready

Development Platform

  • Library of selective GABAAR ligands/medicinal chemistry lead optimization
  • Multiple disease indications
  • Optimized dosing, pharmacokinetic & distribution properties